Psoriasis Market

• Psoriasis is a chronic, immune-mediated inflammatory skin disease characterized by the presence of papules and plaques. It is caused by an overactive immune system that leads to inflammation and a shorter skin cell growth cycle.
• Psoriasis has both pediatric and adult-onset, with the former accounting for more number of cases. Psoriatic patients are frequently categorized into two groups: mild or moderate and moderate to severe psoriasis, depending on the clinical severity of the lesions, the percentage of affected body surface area, and patient quality of life.
• There are different clinical types of psoriasis, the most common of which is plaque psoriasis. People with psoriasis are at a higher risk of developing other complications like psoriatic arthritis, heart attack and stroke, metabolic syndrome, liver and kidney disease, colorectal cancer, and others.
• Although there is no cure for psoriasis, there are multiple effective treatment options. Topical therapy is the standard of care for treatment. Mild to moderate psoriasis can be treated topically with a combination of glucocorticoids, vitamin D analogs, and phototherapy. Systemic treatment is required in moderate to severe cases.
• Therapies approved by the US FDA to treat psoriasis include ENBREL (Etanercept), REMICADE (Infliximab), HUMIRA (Adalimumab), STELARA (ustekinumab), COSENTYX (secukinumab), and others.
• A few therapies that are being investigated for psoriasis include bimekizumab (UCB Biopharma), imsidolimab (AnaptysBio), sonelokimab (MoonLake Immunotherapeutics), EDP-1815 (Evelo Biosciences), and others.
• The total diagnosed prevalent cases of psoriasis in the US comprised ~7,966,000 in 2022 and are projected to increase by 2032.
• The market size of psoriasis in the US is estimated to be around ~USD 17,100 million in 2022.
• Despite its considerable effect on quality of life, psoriasis is underdiagnosed and undertreated. A better understanding of the disease and an increase in available treatment options will aid in optimal management and improve patient outcomes in the coming years.

Report Summary

• The report offers extensive knowledge regarding the psoriasis epidemiology segments and predictions, presenting a deep understanding of the potential future growth in diagnosis rates, disease progression, and treatment guidelines. It provides comprehensive insights into these aspects, enabling a thorough assessment of the subject matter.
• Additionally, an all-inclusive account of the current management techniques and emerging therapies and the elaborative profiles of late-stage (Phase III and Phase II) and prominent therapies that would impact the current treatment landscape and result in an overall market shift has been provided in the report.
• The report also encompasses a comprehensive analysis of the psoriasis market, providing an in-depth examination of its historical and projected market size (2019–2032). It also includes the market share of therapies, detailed assumptions, and the underlying rationale for our methodology.
• The report includes qualitative insights that provide an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, including experts from various hospitals and prominent universities, patient journeys, and treatment preferences that help shape and drive the United States psoriasis market.

The table given below further depicts the key segments provided in the report:

Psoriasis Market

Various key players currently leading the treatment landscape of psoriasis include Amgen, AbbVie, Novartis, Eli Lilly, Janssen Pharmaceuticals, and others. Moreover, various key players are investigating their therapeutic candidates in the late phases of clinical development, which include UCB Biopharma, AnaptysBio, MoonLake Immunotherapeutics, and others. The details of the country-wise and therapy-wise market size have been provided below.

• In 2022, the United States accounted for ~USD 17,000 million, expected to increase by the end of 2032.
• As per DeleveInsight analysis, risankizumab generated the highest revenue of ~USD 2,800 million in 2022.

Psoriasis Therapy Assessment

The section dedicated to drugs in the psoriasis report provides an in-depth evaluation of marketed therapies and the late-stage pipeline drugs (Phase III and Phase II) related to psoriasis.

The drug chapters section provides valuable information on various aspects related to clinical trials of psoriasis, including specific details, such as the pharmacological mechanisms of the drugs involved, designations, approval status, patent information, and a comprehensive analysis of the pros and cons associated with each drug. Furthermore, it presents the most recent news updates and press releases on drugs targeting psoriasis.

Marketed Therapies

ENBREL (Etanercept): Amgen

ENBREL (Etanercept) is a tumor necrosis factor (TNF) blocker, is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kDa (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. It is indicated for treating patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.

REMICADE (Infliximab): Janssen

REMICADE (Infliximab) is a tumor necrosis factor (TNF) blocker and is a chimeric IgG1?monoclonal antibody. It is the only anti-TNF-alpha treatment approved in three different therapeutic areas: gastroenterology, rheumatology, and dermatology. The US FDA approved REMICADE for treating adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis.

COSENTYX (Secukinumab): Novartis

COSENTYX is the first and only fully-human biologic that directly inhibits interleukin-17A (IL-17A), an important cytokine involved in the inflammation and development of moderate to severe plaque psoriasis. The recommended dosage is 300 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks.

Emerging Therapies

Imsidolimab (ANB019): AnaptysBio

Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which is being developed by AnaptysBio as a potential first-in-class therapy for patients suffering from generalized pustular psoriasis (GPP). Currently, two Phase III trials are being evaluated for the treatment of GPP.

Sonelokimab: MoonLake Immunotherapeutics

Sonelokimab (M1095) is an investigational trivalent bi-specific nanobody that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F with the potential to treat inflammatory diseases. It is administered subcutaneously. Sonelokimab has clinically demonstrated potential to drive disease modification in dermatology and rheumatology patients.

JNJ-2113: Protagonist Therapeutics/Janssen Biotech

JNJ-2113 is a novel oral IL-23R antagonist peptide that binds with high affinity to the IL-23R and allows it to be absorbed with oral dosing. The IL-23/IL-23R signaling pathway is critical in the pathogenesis of immune-mediated inflammatory diseases, including psoriasis. JNJ-2113 selectively and potently blocks IL-23 signaling and downstream inflammatory cytokine production.

Psoriasis Market Outlook

Psoriasis is a chronic relapsing disease, which often necessitates long-term therapy. The choice of therapy for psoriasis is determined by disease severity, comorbidities, and access to health care. Clinical disease severity and response to treatment can be graded through several different scores.

A range of agents is available for the symptomatic treatment of psoriasis. Patients with mild-to-moderate psoriasis usually receive topical treatments that modulate gene transcription, inhibit cell proliferation and promote keratinocyte differentiation. These cases can be treated topically with a combination of glucocorticoids, vitamin D analogs, and phototherapy. Major topical agents include corticosteroids, retinoids such as tazarotene, and calcineurin inhibitors such as tacrolimus, vitamin D analogs such as calcipotriene or calcitriol, and combinations such as calcipotriol plus betamethasone dipropionate.

Biologics have emerged as highly potent treatment options in patients for whom traditional systemic therapies fail to achieve an adequate response, are not tolerated owing to adverse effects, or are unsuitable owing to comorbidities. The first biologic agent for psoriasis, the tumor necrosis factor (TNF) antagonist etanercept (ENBREL; Amgen), was approved in 2004. Other approved TNF inhibitors include REMICADE, HUMIRA, and CIMZIA. Other biologics target pro-inflammatory cytokines such as interleukin-12 (IL-12), IL-17, and IL-23. These include STELARA, COSENTYX, SILIQ, SKYRIZI, TREMFYA, and others. Few oral conventional therapies (cyclosporin, methotrexate, and acitretin) are also approved to treat psoriasis.

In a nutshell, plenty of treatment options are available for psoriasis patients; however, each has some potential shortcomings, such as side effects and high costs. To combat these issues, many therapies are currently under different stages of clinical development, which will fuel the market and drive its growth during the forecast period (2021–2032).

Psoriasis Understanding and Treatment

Psoriasis Overview

Psoriasis is a long-lasting, noncontagious autoimmune disease where the immune system mistakenly attacks the body’s cells, characterized by raised areas of abnormal skin. Signs and symptoms of psoriasis vary by person and by type of disease. The most common psoriasis symptoms include thick red patches of skin with silvery-white scales, ridged or pitted nails, swollen or painful joints, and cracked skin that flakes or bleeds. Common signs of psoriasis are often found on the elbows, knees, and scalp, but psoriasis can also develop on the hands, nails, face, genitals, or feet. The different clinical types of psoriasis include plaque, inverse, pustular, guttate, and erythrodermic psoriasis.

Psoriasis diagnosis

The diagnosis of psoriasis is found to be mostly on a clinical basis. The hallmarks observed in the case of patients affected with psoriasis are well-demarcated, symmetric, and erythematous plaques with overlying silvery scales. A skin biopsy may help determine the type of psoriasis and rule out other disorders. Dermatologists usually perform a punch biopsy to puncture the skin and remove a small tissue sample.

Further details related to country-based variations are provided in the report…

Psoriasis treatment

Treatments are determined by the type and severity of psoriasis and the area of skin affected. Psoriasis treatment aims to relieve symptoms like itch and improve skin health. Effective treatment of psoriasis not only manages skin symptoms but may also help reduce inflammation in the body that could lead to other diseases. Although there is no cure for psoriasis, multiple treatment options include topical therapy (creams and ointments), phototherapy, and systemic treatment (oral and injected medications that work throughout the entire body).

Topical steroids are one of the most common topical treatments for psoriasis. A combination of glucocorticoids and vitamin D analogs treats mild to moderate psoriasis. UVB phototherapy treatment involves exposing the skin to an artificial UVB light source for a set time regularly and is effective for some types of psoriasis that have not responded to topical treatments. Systemic treatment is required in moderate to severe cases.

Further details related to treatment and management are provided in the report…

Psoriasis Epidemiology

The psoriasis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Psoriasis, Age-specific Cases of Psoriasis, Type-specific cases of Psoriasis, Location-specific cases of Psoriasis, Severity-specific cases of psoriasis, and Total Treated cases of Psoriasis in the United States from 2019 to 2032.

• In 2022, the total diagnosed prevalent cases of psoriasis in the US were ~7,966,000, projected to increase during the forecast period (2023–2032).
• As per DelveInsight analysis, the total age-specific cases of psoriasis in pediatrics and adults in the US were 73,882 and 7,891,846 cases in 2022.
• Plaque psoriasis is the most common form of psoriasis, accounting for ~80% of the total cases in the US in 2022.
• The majorly affected area by psoriasis was observed to be Genital, with 5,310,751 cases in 2022. These cases are estimated to increase by 2032.
• Severity-specific cases of psoriasis in the US were observed to be 6,253,096 and 1,712,631 for mild and moderate-to-severe, respectively, in 2022.
• As per Delveinsight’s analysis in 2022, treated cases from oral, biologic, can topical were 301,423, 263,745, and 188,389, respectively.

Further details related to epidemiology will be provided in the report…

KOL Views

To stay abreast of the latest trends in the market, we conduct primary research by seeking the opinions of Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) who work in the relevant field. This helps us fill any gaps in data and validate our secondary research.

We have reached out to industry experts to gather insights on various aspects of psoriasis, including the evolving treatment landscape, patients’ reliance on conventional therapies, their acceptance of therapy switching, drug uptake, and challenges related to accessibility. The experts we contacted included medical/scientific writers, professors, and researchers from prestigious universities in the United States.

Our team of analysts at Delveinsight connected with more than 20 KOLs in the United. We contacted institutions such as the National Psoriasis Foundation, Oregon Medical Research Center, Johns Hopkins University, University of Pennsylvania, and others. By obtaining the opinions of these experts, we gained a better understanding of the current and emerging treatment patterns in the psoriasis market, which will assist our clients in analyzing the overall epidemiology and market scenario.

Qualitative Analysis

We perform Qualitative and Market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in trials for psoriasis, one of the most important primary endpoints was the Investigator Global Assessment (IGA) to measure the proportion of patients achieving scores of “clear” or “almost clear.” Based on these, the overall efficacy is evaluated.

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Because newly authorized drugs are often expensive, some patients escape receiving proper treatment or use off-label, less expensive prescriptions. Reimbursement plays a critical role in how innovative treatments can enter the market. The cost of the medicine, compared to the benefit it provides to patients who are being treated, sometimes determines whether or not it will be reimbursed. Regulatory status, target population size, the setting of treatment, unmet needs, the number of incremental benefit claims, and prices can all affect market access and reimbursement possibilities.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Psoriasis Report Insights

• Patient Population
• Therapeutic Approaches
• Psoriasis Market Size and Trends
• Existing Market Opportunity

Psoriasis Report Key Strengths

• Ten Year Forecast
• The United States Coverage
• Psoriasis Epidemiology Segmentation
• Key Cross Competition

Psoriasis Report Assessment

• Current Treatment Practices
• Unmet Needs
• Market Attractiveness
• Qualitative Analysis (SWOT, Conjoint Analysis)

Key Questions

• Would there be any changes in the treatment approach?
• Will there be any improvements in management recommendations for psoriasis?
• Would research and development advances pave the way for future tests and therapies for psoriasis?
• Would the diagnostic testing space experience a significant impact and lead to a positive shift in the treatment landscape of psoriasis?
• What kind of uptake will the new therapies witness in the coming years in psoriasis patients?